Brown Christopher D. sold $170K of MASS

Brown Christopher D. sold 20,000 shares of 908 Devices Inc. (MASS) at $8.49 ($0.17M total) on 2026-08-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Brown Christopher D.
Published Aug 7, 2026, 8:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 7, 2026, 9:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MASS
Neutral
medium confidence
Mentioned
$MASS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MASSNeutralLow
01

Why it matters

The newest disclosed fact is the director’s scheduled open-market sale of 20,000 shares at a stated price, with holdings after the trade reported.

02

Market read

Insider selling headlines can create short-term sentiment noise, but 10b5-1 plans usually limit interpretive weight.

03

What to watch

The filing does not disclose reasons for the sale, and the net effect depends on whether other insiders or the company have concurrent catalysts not mentioned here.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-07, transaction dated 2026-08-05

Background

This is an SEC Form 4 insider transaction disclosure for 908 Devices Inc. (MASS).

Company-level read

Ticker impact

$MASSNeutralMedium confidence
Context

SEC Form 4 shows director Christopher D. Brown sold 20,000 shares of MASS at $8.49 on 2026-08-05 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any impact is likely short-lived unless accompanied by other company-specific news.

Evidence & confidence

The filing is an open-market sale by a director, explicitly under a pre-arranged 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.

Market effects

No clear sector read-through from a single director 10b5-1 sale.

None indicated.

None indicated.

Counterpoint

Traders may treat 10b5-1 sales as noise; the sale could be purely scheduled liquidity rather than a bearish view.

Key entities

  • 908 Devices Inc.

    Company whose director insider sale is disclosed on Form 4.

  • Christopher D. Brown

    Director who sold 20,000 shares under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MASSHigh

908 Devices Inc (MASS) (Q3 2026) Earnings Call Highlights: Record $19 Million Revenue

908 Devices Inc (MASS) reported Q3 2026 revenue of $19M, up 35% YoY, driven by FTIR products and NearLab sales. The company raised full-year revenue guidance to $68.5M-$70M. Adjusted EBITDA loss narrowed to $1.7M, but gross margin decreased to 58%. MASS shipped 300+ devices, bringing the installed base to 4,400. NearLab integration is progressing, with 100 devices sold in Q3. The company remains unprofitable, with a net loss of $4.6M and $2.4M cash burn.

$MASSMed

908 Devices Q3 2026 slides: 35% growth, raised guidance

908 Devices (NASDAQ:MASS) reported 35% YoY revenue growth to $19.0M in Q3 2026, raising full-year guidance to $68.5M-$70.0M. Shares fell 4.43% premarket. The company focuses on chemical detection tools for public safety and defense, with FTIR products contributing 55% of revenue. Despite narrowing losses, concerns remain over customer concentration and adjusted EBITDA losses.

$MASSMed

908 Devices Reports Third Quarter 2026 Financial Results and Achieves Record Revenue

908 Devices Inc. (MASS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ ​ 908 Devices Reports Third Quarter 2026 Financial Results and Achieves Record Revenue Revenue increased 35% compared to prior year Raises low end of 2026 revenue outlook ​ ​ BURLINGTON, Mass. – November 10, 2026 – 908 Devices Inc. (Nasdaq: MASS), a core small-cap

$MASSMed

908 Devices Inc. Q2 2026 Earnings Call Summary

908 Devices reported Q2 2026 revenue up 23%, driven by U.S. state and local demand for fentanyl and synthetic drug detection. VipIR saw 35+ shipments, and the NIRLAB acquisition added an AI subscription model. Full-year 2026 revenue guidance was raised to $68m-$70m. Adjusted EBITDA loss narrowed 50% YoY; recurring revenue target is 30%+.

$MASSMedAI 8/10

908 Devices Q2 Earnings Call Highlights

908 Devices (NASDAQ: MASS) reported Q2 operating expenses of $21.2M, down from $21.5M, and narrowed net loss from continuing operations to $11.9M. Adjusted EBITDA loss improved to $1.9M. Cash and marketable securities were $101.5M with no debt. The company raised 2026 revenue guidance to $68M-$70M and expects recurring revenue of $4.9M (31%).